Skip to main content

Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Written by Customer Service on . Posted in Public Companies.

ORION CORPORATION PRESS RELEASE 18 JANUARY 2021 at 9.00 EET             
         Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania  Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.The U.S. Food and Drug Administration FDA granted approval for Orion’s Clevor®, an eye drop indicated for the induction of vomiting in dogs, in June 2020. Under the terms of the related agreement, Vetoquinol will have the right to sell and market Clevor® (ropinirole) in the USA.On August 1st  2020, Vetoquinol acquired the rights for the Drontal® and Profender® products in the EU and the UK. Effective January 1st 2021, Orion will have the right to sell and market Vetoquinol’s Drontal® and Profender® products in Finland, Hungary and Romania. Drontal® product range is used for the treatment and control of internal parasites in cats and dogs and Profender® for the treatment and control of internal parasites in cats.These new distribution agreements expand the current collaboration between the two companies under which Vetoquinol has been distributing Orion Animal Health’s sedative products in several European countries since February 2015.“I’m very pleased to expand our fruitful collaboration with Vetoquinol and have a trusted partner to distribute the latest approved Orion Animal Health innovation in the USA. Also, it is important for us that we can continue to sell Drontal® and Profender® in our home market Finland and expand the distribution to Hungary and Romania”, says Niclas Lindstedt, Vice President of Orion Animal Health.“We are delighted to reinforce our partnership with Orion. Our Drontal® and Profender® product ranges will benefit from an efficient distribution network in Finland, Hungary and Romania. Moreover, Vetoquinol is proud to be the veterinary laboratory chosen by Orion to develop this innovative Clevor® (ropinirole) brand in the USA. This is a new milestone in our cooperation that demonstrates Vetoquinol’s strong pharmaceutical capabilities and expertise in this key market”, says Matthieu Frechin, CEO of Vetoquinol.About Orion
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion’s net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in more than 100 countries through to 24 subsidiaries established in Europe, the Americas and the Asia/Pacific, and a global Export division. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2020, Vetoquinol employs 2,401 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).Contact persons:ORIONVETOQUINOLFanny Toillon, Investor Relations, Vetoquinol
Tel. +33 (03) 84 62 59 88
relations.investisseurs@vetoquinol.com
Emmanuel Dovergne, Investor and Media Relations, Keima Communication
Tel. +33 (0)1 56 43 44 63
Emmanuel.dovergne@keima.frPublisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.